These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37916694)

  • 1. Methadone use for acute opioid withdrawal in Tshwane shelters during the COVID-19 lockdown.
    Siemens JA; Bhoora U; Janse van Rensburg M
    S Afr Fam Pract (2004); 2023 Sep; 65(1):e1-e7. PubMed ID: 37916694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting.
    Bhoora U; Gloeck NR; Scheibe A
    Afr J Prim Health Care Fam Med; 2022 Sep; 14(1):e1-e9. PubMed ID: 36226932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mental health symptoms among homeless shelter residents during COVID-19 lockdown in Tshwane, South Africa.
    Stonehouse J; Grobler G; Bhoora U; Janse van Rensburg MNS
    Afr J Prim Health Care Fam Med; 2023 Apr; 15(1):e1-e8. PubMed ID: 37042538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harm reduction in an emergency response to homelessness during South Africa's COVID-19 lockdown.
    Marcus TS; Heese J; Scheibe A; Shelly S; Lalla SX; Hugo JF
    Harm Reduct J; 2020 Aug; 17(1):60. PubMed ID: 32831083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting 6-month retention among people with opioid use disorders accessing outpatient methadone maintenance therapy in Tshwane, South Africa.
    Gloeck NR; Harris BN; Webb EM; Scheibe A
    S Afr Med J; 2020 Dec; 111(1):68-73. PubMed ID: 33404009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of comorbid disease and associated risk factors among homeless people living in temporary shelters during the COVID-19 lockdown in Tshwane, South Africa.
    Phiri TV; Gloeck N; Musekiwa A
    S Afr Med J; 2023 Sep; 113(9):48-52. PubMed ID: 37882135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa.
    Goeieman DS; Nonyane DS; Nzaumvila DK; Anse van Rensburg MNS
    Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e10. PubMed ID: 36744456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
    Aldabergenov D; Reynolds L; Scott J; Kelleher MJ; Strang J; Copeland CS; Kalk NJ
    Int J Drug Policy; 2022 Dec; 110():103877. PubMed ID: 36265326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs.
    Lake S; Kerr T; Buxton J; Walsh Z; Cooper ZD; Socías ME; Fairbairn N; Hayashi K; Milloy MJ
    Cannabis Cannabinoid Res; 2023 Feb; 8(1):155-165. PubMed ID: 34813374
    [No Abstract]   [Full Text] [Related]  

  • 10. The demography and disease burden of the homeless shelter population of Tshwane during COVID-19.
    Germishuys PS; Smith S; Hugo J; Madela-Mntla E; Botha T
    Afr J Prim Health Care Fam Med; 2022 Dec; 14(1):e1-e8. PubMed ID: 36546493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2003; (2):CD002024. PubMed ID: 12804419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002024. PubMed ID: 15495025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003409. PubMed ID: 15495052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chart review comparing paregoric to methadone in the treatment of neonatal opioid withdrawal.
    Wunsch MJ
    J Addict Dis; 2006; 25(3):27-33. PubMed ID: 16956866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2001; (1):CD002024. PubMed ID: 11279747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2002; (2):CD003409. PubMed ID: 12076479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2003; (3):CD003409. PubMed ID: 12917966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Things We Do for No Reason™: Avoiding methadone for opioid withdrawal.
    Martin M; Englander H; Calcaterra SL
    J Hosp Med; 2023 Nov; 18(11):1034-1037. PubMed ID: 37244869
    [No Abstract]   [Full Text] [Related]  

  • 19. Patterns of symptom complaints in methadone maintenance patients.
    Dyer KR; White JM
    Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.